Nicholas Piramal Healthy Q4 numbers

Nicholas Piramal India surged 3.29% to Rs 341 at 15:08 IST on BSE after reporting 317.16% rise in net profit to Rs 112.3 crore on 33.51% growth in net sales to Rs 516.98 crore in Q4 March 2008 over Q4 March 2007.

The stock hit a high of Rs 347 and a low of Rs 335 so far during the day. The stock had a 52-week high of Rs 383 on 19 December 2007 and a 52-week low of Rs 231.25 on 21 August 2007.

The company’s current equity is Rs 41.80 crore. Face value per share is Rs 2.

The current price of Rs 341 discounts its Q3 December 2007 EPS of Rs 14.13, by a PE multiple of 24.13.

Nicholas Piramal India’s net profit rose 60.12% to Rs 301.48 crore on 18.18% growth in total income to Rs 1,938.07 crore on FY 2008 over FY 2007.

On 15 April 2008, Nicholas Piramal signed an agreement with Khandelwal Laboratories for the purchase of its anti-spasmodic Anafortan and antibiotic CEFI brands for a total consideration of Rs 116 crore.

In January 2008, the company acquired pharmaceuticals business of Healthline, Bangalore for a consideration of Rs 15 crore.

Nicholas Piramal India is one among the top ten pharmaceutical contract-manufacturing firms in the world.